Biomedical Engineering Reference
In-Depth Information
5. Ericsson UB, Hallberg BM, Detitta GT,
Dekker N, Nordlund P (2006) Thermofluor-
based high-throughput stability optimization
of proteins for structural studies. Anal
Biochem 357:289-298
6. Niesen FH, Berglund H, Vedadi M (2007)
The use of differential scanning fluorimetry to
detect ligand interactions that promote pro-
tein stability. Nat Protoc 2:2212-2221
7. Alexandrov AI, Mileni M, Chien EY, Hanson
MA, Stevens RC (2008) Microscale fluores-
cent thermal stability assay for membrane pro-
teins. Structure 16:351-359
8. Nayar R, Manning MC (2002) High through-
put formulation: strategies for rapid develop-
ment of stable protein products. Pharm
Biotechnol 13:177-198
9. Ulloa-Aguirre A, Janovick JA, Brothers SP,
Conn PM (2004) Pharmacologic rescue of
conformationally-defective proteins: implica-
tions for the treatment of human disease.
Traffic 5:821-837
10. Loo TW, Clarke DM (2007) Chemical and
pharmacological chaperones as new therapeu-
tic agents. Expert Rev Mol Med 9:1-18
11. Pedemonte N, Lukacs GL, Du K, Caci E,
Zegarra-Moran O, Galietta LJ, Verkman AS
(2005) Small-molecule correctors of defective
DeltaF508-CFTR cellular processing identi-
fied by high-throughput screening. J Clin
Invest 115:2564-2571
12. Tropak MB, Blanchard JE, Withers SG,
Brown ED, Mahuran D (2007) High-
throughput screening for human lysosomal
beta-N-Acetyl hexosaminidase inhibitors act-
ing as pharmacological chaperones. Chem
Biol 14:153-164
13. Pey AL, Ying M, Cremades N, Velazquez-
Campoy A, Scherer T, Thony B, Sancho J,
Martinez A (2008) Identification of pharma-
cological chaperones as potential therapeutic
agents to treat phenylketonuria. J Clin Invest
118:2858-2867
14. McInnes C (2007) Virtual screening strate-
gies in drug discovery. Curr Opin Chem Biol
11:494-502
15. Tanrikulu Y, Schneider G (2008)
Pseudoreceptor models in drug design: bridg-
ing ligand- and receptor-based virtual screen-
ing. Nat Rev Drug Discov 7:667-677
16. Hanson MA, Cherezov V, Griffith MT, Roth
CB, Jaakola VP, Chien EY, Velasquez J, Kuhn
P, Stevens RC (2008) A specific cholesterol
binding site is established by the 2.8 A struc-
ture of the human beta2-adrenergic receptor.
Structure 16:897-905
17. Desviat LR, Perez B, Ugarte M (2003)
Investigation of folding and degradation of
in vitro synthesized mutant proteins in the
cytosol. Methods Mol Biol 232:257-263
18. Martinez A, Calvo AC, Teigen K, Pey AL
(2008) Chapter 3 Rescuing proteins of low
kinetic stability by chaperones and natural
ligands: phenylketonuria, a case study. Prog
Nucleic Acid Res Mol Biol 83:89-134
19. Hanson MA, Stevens RC (2009) Discovery of
new GPCR biology: one receptor structure at
a time. Structure 17:8-14
20. MartÃnez A, Knappskog PM, Olafsdottir S,
Døskeland AP, Eiken HG, Svebak RM,
Bozzini M, Apold J, Flatmark T (1995)
Expression of recombinant human phenylala-
nine hydroxylase as fusion protein in
Escherichia coli circumvents proteolytic deg-
radation by host cell proteases Isolation and
characterization of the wild-type enzyme.
Biochem J 306:589-597
21. Rosenbaum DM, Cherezov V, Hanson MA,
Rasmussen SG, Thian FS, Kobilka TS, Choi
HJ, Yao XJ, Weis WI, Stevens RC, Kobilka
BK (2007) GPCR engineering yields high-
resolution structural insights into beta2-
adrenergic
receptor
function.
Science
318:1266-1273
22. Irun MP, Maldonado S, Sancho J (2001)
Stabilization of apoflavodoxin by replacing
hydrogen-bonded charged Asp or Glu resi-
dues by the neutral isosteric Asn or Gln.
Protein Eng 14:173-181
23. Senisterra GA, Soo Hong B, Park HW, Vedadi
M (2008) Application of high-throughput
isothermal denaturation to assess protein sta-
bility and screen for ligands. J Biomol Screen
13:337-342
24. Thony B, Calvo AC, Scherer T, Svebak RM,
Haavik J, Blau N, Martinez A (2008)
Tetrahydrobiopterin shows chaperone activity
for
tyrosine
hydroxylase.
J
Neurochem
106:672-681
25. Thony B, Ding Z, Martinez A (2004)
Tetrahydrobiopterin protects phenylalanine
hydroxylase activity in vivo: implications for
tetrahydrobiopterin-responsive hyperphenyla-
laninemia. FEBS Lett 577:507-511